<DOC>
	<DOCNO>NCT00005985</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : This phase II trial study well give filgrastim together chemotherapy peripheral stem cell transplant work treat patient Hodgkin 's lymphoma non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Filgrastim Chemotherapy Followed Peripheral Stem Cell Transplant Treating Patients With Hodgkin 's Lymphoma Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess clinical outcome , survival , morbidity transplantation patient Hodgkin 's lymphoma non-Hodgkin 's lymphoma treat filgrastim ( G-CSF ) follow high dose chemotherapy plus G-CSF follow autologous peripheral blood stem cell ( PBSC ) transplantation . - Determine whether sufficient PBSC collect use autologous transplantation patient mobilize hematopoietic growth factor alone compare chemotherapy plus growth factor . - Determine whether primed PBSC support prompt lymphoid myeloid hematopoietic recovery transplantation patient . - Compare number commit progenitor cell and/or primitive , pluripotential hematopoietic stem cell two prim technique . - Compare number tumor cell cryopreserved PBSC follow prim technique . - Evaluate response extend relapse free survival conjunction rapid hematopoietic reconstitution limit transplant associate morbidity mortality patient treat regimen . OUTLINE : In first priming phase , patient receive filgrastim ( G-CSF ) subcutaneously ( SQ ) daily day 1-7 peripheral blood stem cell collect day 6-8 . At least 48 hour last dose G-CSF third leukapheresis , patient receive second priming , consist cyclophosphamide IV 2 hour day 1 cytarabine IV 1 hour every 12 hour total 2 dos day 1 . Patients also receive mitoxantrone IV 1 hour daily dexamethasone IV every 12 hour total 4 dos day 1-2 . Patients receive G-CSF SQ daily begin day 4 continue completion leukapheresis . PBSC collect 3 consecutive day blood count recover . In transplant phase , patient non-Hodgkin 's lymphoma exceed pretransplant radiotherapy limit receive cyclophosphamide IV 2 hour day -7 -6 total body irradiation twice daily day -4 -1 . Autologous PBSC reinfused day 0 . Patients receive G-CSF IV daily begin day 0 continue day 21 blood count recover . Patients Hodgkin 's lymphoma patient non-Hodgkin 's lymphoma exceed pretransplant radiotherapy limit receive cyclophosphamide IV 2 hour daily day -6 -3 , carmustine IV 1 hour day -6 , etoposide IV 4 hour every 12 hour total 6 dos day -6 -4 . Autologous PBSC reinfused day 0 . Patients also receive G-CSF IV daily begin day 0 continue day 21 blood count recover . All patient receive radiotherapy residual nodal mass measure least 2 cm 5 day week begin day 28 . Patients follow day 100 , every 3 month 1 year , every 6 month 2 year , annually thereafter . This change treatment guideline study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically confirm diagnosis High grade nonHodgkin 's lymphoma : Immunoblastic small noncleaved cell lymphoma ( Burkitt 's nonBurkitt 's ) complete partial remission initial therapy Localized ( stage I Zeigler stage A ) small noncleaved ( Burkitt 's nonBurkitt 's ) relapse incomplete response initial therapy Lymphoblastic lymphoma second great complete partial response High risk lymphoblastic lymphoma first complete remission initial therapy ( high risk factor include stage IV disease , LDH great 2 time normal , 2 extranodal site ) Intermediate grade nonHodgkin 's lymphoma : Diffuse large cell lymphoma Diffuse mix cell lymphoma Diffuse small cleave cell lymphoma Follicular large cell lymphoma In second great complete partial remission OR High risk first complete remission initial therapy High risk feature include : No complete response 12 week initial combination chemotherapy Bulky disease ( great 10 cm nodal mass mediastinal disease involve great 1/3 chest diameter Malignant pleural effusion Liver involvement LDH great 2 time upper limit normal diagnosis At least 2 extranodal site Low grade nonHodgkin 's lymphoma : Follicular small cleave cell lymphoma Follicular mix cell lymphoma Diffuse small lymphocytic lymphoma In first great complete response OR Following initial treatment complete response achieve In second great complete partial response treat diagnosis without clinical symptom necessitate treatment Tcell lymphoma ( nonlymphoblastic , intermediate , high grade lymphoma ) initial therapy whether complete response achieve Hodgkin 's lymphoma Stage I II disease treat primary radiotherapy failure least one combination chemotherapy regimen Stage III IV disease failure mechlorethamine , vincristine , procarbazine , prednisone ( MOPP ) like regimen , alternative noncross resistant regimen ( e.g. , doxorubicin , bleomycin , vinblastine , dacarbazine [ ABVD ] ) , combination ( e.g. , MOPPABV ) High risk feature allow include : Failure achieve initial complete remission MOPP and/or ABVD crossover hybrid therapy Relapse within 6 month initial therapy Relapse initial radiotherapy complete response longer 1 year since initial therapy subsequent failure MOPP and/or ABVD hybrid Bulky mediastinal disease initial therapy residual mass least 5 cm feature persist disease ( e.g. , Gallium scan positive , high LDH , enlarge serial xrays , positive biopsy ) No HIV HTLV1 associate lymphomas No resistant refractory lymphoma ( partial response follow 3 course combination chemotherapy ) No active ischemic degenerative CNS disease NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 70 Performance status : Age 6570 year : Karnofsky 80100 % Under 65 year : ECOG 01 ( 2 allow symptom directly relate lymphoma ) Life expectancy : Greater 8 week Hematopoietic : Not specify Hepatic : No prior current chronic liver disease Bilirubin great 1.5 mg/dL AST alkaline phosphatase less 2 time normal Renal : Age 6570 year : Creatinine clearance great 60 mL/min ( creatinine least 1.5 mg/dL ) Under 65 year : Creatinine great 1.5 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : LVEF least 45 % MUGA No symptoms cardiac disease No active ischemic heart disease No uncontrolled hypertension Pulmonary : Age 6570 year : If history smoking respiratory symptom , spirometry DLCO must great 50 % predict All age : No obstructive airway disease No resting hypoxemia ( PO_2 less 80 ) DLCO least 50 % predict Other : No poorly control diabetes PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Must prior chemotherapy attempt achieve complete response Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No radiotherapy residual disease prior transplantation Surgery : Not specify Other : Concurrent IV antibiotic therapy allow fever sign infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>